Slow Bull
The market, slowly. FRIDAY, 25 SEPTEMBER 2026
← All news
Markets

Boulevard starts up with $65M to pursue targeted autoimmune drugs

1 source ·1 article ·Aug 12, 10:30 UTC

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·Aug 12, 10:30 UTC

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.